484.96

1.39% 6.64

Pre-market: 486.15 1.19 +0.25%

Thermo Fisher Scientific Inc (TMO)

Overview News Price History Option Chain Financials Why TMO Down? Discussions Forecast Stock Split Dividend History

Thermo Fisher Scientific Inc stock is traded at $484.96, with a volume of 3.41M. It is up +1.39% in the last 24 hours and up +18.78% over the past month. Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Previous Close:

$478.32

Open:

$475.44

24h Volume:

3.41M

Relative Volume:

1.21

Market Cap:

$183.07B

Revenue:

$43.21B

Net Income/Loss:

$6.58B

P/E Ratio:

28.05

EPS:

17.29

Net Cash Flow:

$6.17B

1W Performance:

+19.76%

1M Performance:

+18.78%

6M Performance:

-17.00%

1Y Performance:

-20.12%

1-Day Range:

$474.87

$487.11

1-Week Range:

$405.15

$487.11

52-Week Range:

$385.46

$627.88

Thermo Fisher Scientific Inc Stock (TMO) Company Profile

Name

Thermo Fisher Scientific Inc

Sector

Healthcare (1164)

Industry

Diagnostics & Research (54)

Phone

(781) 622-1000

Address

168 THIRD AVENUE, WALTHAM, MA

Employee

125,000

Twitter

@thermofisher

Next Earnings Date

2025-07-23

Latest SEC Filings

TMO's Discussions on Twitter

Compare TMO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TMO Thermo Fisher Scientific Inc	484.96	180.56B	43.21B	6.58B	6.17B	17.29
DHR Danaher Corp	202.94	147.13B	24.01B	3.41B	4.86B	4.70
IDXX Idexx Laboratories Inc	566.50	45.45B	3.93B	894.97M	837.70M	10.82
A Agilent Technologies Inc	119.54	34.14B	6.63B	1.17B	1.19B	4.05
IQV Iqvia Holdings Inc	197.76	33.86B	15.50B	1.33B	2.16B	7.34

Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-24-25	Downgrade	HSBC Securities	Buy → Hold
Jul-11-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jul-09-25	Downgrade	UBS	Buy → Neutral
Jan-10-25	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-23-24	Initiated	Scotiabank	Sector Perform
Oct-14-24	Initiated	Redburn Atlantic	Buy
Oct-01-24	Initiated	Stephens	Overweight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-03-24	Resumed	Jefferies	Buy
Mar-18-24	Resumed	Citigroup	Neutral
Jan-24-24	Downgrade	Barclays	Overweight → Equal Weight
Jan-08-24	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-18-23	Initiated	HSBC Securities	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-26-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-25-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Sep-28-23	Initiated	Bernstein	Outperform
Sep-06-23	Resumed	Citigroup	Buy
Jul-19-23	Initiated	Raymond James	Outperform
Jul-19-23	Reiterated	Robert W. Baird	Outperform
Jul-13-23	Upgrade	Credit Suisse	Neutral → Outperform
Apr-04-23	Reiterated	Barclays	Overweight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-27-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Neutral
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Jan-26-22	Resumed	Barclays	Overweight
Oct-20-21	Upgrade	Citigroup	Neutral → Buy
Oct-15-21	Resumed	Cowen	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-16-21	Initiated	The Benchmark Company	Buy
Mar-18-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-03-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Neutral → Outperform
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Initiated	Goldman	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Sep-14-20	Initiated	Morgan Stanley	Overweight
Aug-20-20	Resumed	JP Morgan	Overweight
Jul-15-20	Upgrade	Cleveland Research	Neutral → Buy
Jul-07-20	Reiterated	Needham	Buy
Apr-23-20	Reiterated	Needham	Buy
Jan-31-20	Reiterated	Needham	Buy
Jan-22-20	Initiated	Credit Suisse	Neutral
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Buy
Nov-15-19	Initiated	Stifel	Buy
Jul-25-19	Reiterated	Needham	Buy
Jul-16-19	Downgrade	Needham	Strong Buy → Buy
May-30-19	Initiated	Wolfe Research	Outperform
May-23-19	Reiterated	Needham	Strong Buy
Apr-22-19	Reiterated	Needham	Strong Buy
Apr-16-19	Reiterated	BofA/Merrill	Buy

View All

Thermo Fisher Scientific Inc Stock (TMO) Latest News

04:34 AM

North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire

04:34 AM

04:31 AM

North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - GlobeNewswire Inc.

04:31 AM

Jul 28, 2025

Thermo Fisher Scientific’s SWOT analysis: stock outlook amid market shifts - Investing.com

Jul 28, 2025

COVID-19 Saliva-Based Detection Kits Market to reach US$ 1.2 Bn - openPR.com

Jul 28, 2025

Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025 - Bluefield Daily Telegraph

Jul 28, 2025

Cell Reprogramming Market Future Business Opportunities - openPR.com

Jul 28, 2025

Thermo Fisher Scientific's (TMO) Q2 Outperformance and Revised Price Target: Is Now the Time to Buy? - AInvest

Jul 28, 2025

Refurbished Laboratory Equipment Market Top Companies Study - openPR.com

Jul 28, 2025

Barclays Lifts PT on Thermo Fisher Scientific (TMO) to $490 From $450 - Insider Monkey

Jul 28, 2025

TD Cowen Sees Upside for Thermo Fisher (TMO) With Modest Q2 Growth - Insider Monkey

Jul 28, 2025

Jul 27, 2025

When is Thermo Fisher Scientific Inc. stock expected to show significant growthDiscover high-impact investment opportunities - jammulinksnews.com

Jul 27, 2025

Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio? - Benzinga

Jul 27, 2025

Jul 26, 2025